ISDA

Entry Detail

PDB ID:

6T2W

Keywords:

TRANSFERASE

Title:

Crystal structure of the CSF1R kinase domain with a dihydropurinone inhibitor (compound 4)

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Spodoptera frugiperda

PDB Version:

Deposition Date:

2019-10-09

Release Date:

2020-01-01

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.70 Å

R-Value Free:

0.18

R-Value Work:

0.16

R-Value Observed:

0.16

Space Group:

H 3

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Macrophage colony-stimulating factor 1 receptor
Chain IDs:A
Chain Length:332
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P07333 Pfam ID:PF07714 EC:2.7.10.1

Ligand Molecules

M9T

SO4

Primary Citation

The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor.

Goldberg, F.W, Finlay, M.R.V, Ting, A.K.T, Beattie, D, Lamont, G.M, Fallan, C, Wrigley, G.L, Schimpl, M, Howard, M.R, Williamson, B, Vazquez-Chantada, M, Barratt, D.G, Davies, B.R, Cadogan, E.B, Ramos-Montoya, A, Dean, E.Show

J.Med.Chem. 63 3461 3471 (2020)

PMID: 31851518 DOI: 10.1021/acs.jmedchem.9b01684

Abstact

DNA-PK is a key component within the DNA damage response, as it is responsible for recognizing and repairing double-strand DNA breaks (DSBs) via non-homologous end joining. Historically it has been challenging to identify inhibitors of the DNA-PK catalytic subunit (DNA-PKcs) with good selectivity versus the structurally related PI3 (lipid) and PI3K-related protein kinases. We screened our corporate collection for DNA-PKcs inhibitors with good PI3 kinase selectivity, identifying compound 1. Optimization focused on further improving selectivity while improving physical and pharmacokinetic properties, notably co-optimization of permeability and metabolic stability, to identify compound 16 (AZD7648). Compound 16 had no significant off-target activity in the protein kinome and only weak activity versus PI3Kα/γ lipid kinases. Monotherapy activity in murine xenograft models was observed, and regressions were observed when combined with inducers of DSBs (doxorubicin or irradiation) or PARP inhibition (olaparib). These data support progression into clinical studies (NCT03907969).

Legend

Protein

Chemical

Disease

Primary Citation of related structures